286 related articles for article (PubMed ID: 25789974)
21. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
23. Role of Krüppel-like Factor 4-p21
Kim SH; Singh SV
Cancer Prev Res (Phila); 2019 Mar; 12(3):125-134. PubMed ID: 30723175
[TBL] [Abstract][Full Text] [Related]
24. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
25. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
26. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
28. Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.
Yori JL; Seachrist DD; Johnson E; Lozada KL; Abdul-Karim FW; Chodosh LA; Schiemann WP; Keri RA
Neoplasia; 2011 Jul; 13(7):601-10. PubMed ID: 21750654
[TBL] [Abstract][Full Text] [Related]
29. NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
Bailey ST; Miron PL; Choi YJ; Kochupurakkal B; Maulik G; Rodig SJ; Tian R; Foley KM; Bowman T; Miron A; Brown M; Iglehart JD; Debajit KB
Mol Cancer Res; 2014 Mar; 12(3):408-420. PubMed ID: 24319068
[TBL] [Abstract][Full Text] [Related]
30. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
31. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
[TBL] [Abstract][Full Text] [Related]
32. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Corcoran C; Rani S; Breslin S; Gogarty M; Ghobrial IM; Crown J; O'Driscoll L
Mol Cancer; 2014 Mar; 13():71. PubMed ID: 24655723
[TBL] [Abstract][Full Text] [Related]
33. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
34. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
36. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
37. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Rhee J; Han SW; Cha Y; Ham HS; Kim HP; Oh DY; Im SA; Park JW; Ro J; Lee KS; Park IH; Im YH; Bang YJ; Kim TY
Breast Cancer Res Treat; 2011 Jan; 125(1):107-14. PubMed ID: 20936340
[TBL] [Abstract][Full Text] [Related]
38. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
39. Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Tilio M; Gambini V; Wang J; Garulli C; Kalogris C; Andreani C; Bartolacci C; Elexpuru Zabaleta M; Pietrella L; Hysi A; Iezzi M; Belletti B; Orlando F; Provinciali M; Galeazzi R; Marchini C; Amici A
Cancer Lett; 2016 Oct; 381(1):76-84. PubMed ID: 27475932
[TBL] [Abstract][Full Text] [Related]
40. Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
Estévez LG; Suarez-Gauthier A; García E; Miró C; Calvo I; Fernández-Abad M; Herrero M; Marcos M; Márquez C; Lopez Ríos F; Perea S; Hidalgo M
Breast Cancer Res; 2014 Sep; 16(4):R76. PubMed ID: 25186428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
